Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
Clinical trial NCT04743804 · TERMINATED
Trial details
- NCT number
- NCT04743804
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-29
- Primary completion
- 2022-12-22
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.